Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04190888 · ClinicalTrials.gov registry record
Sickle Cell Uric Acid (SCUA) - Cohort Repository
A clinical trial of Sickle Cell Disease and Chronic Kidney Diseases, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 78
- Enrollment target
- 1
- Study location
NCT04190888 is a study of Sickle Cell Disease and Chronic Kidney Diseases that has completed, run by Virginia Commonwealth University. The registered enrollment target is 78 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04190888, a study of Sickle Cell Disease and Chronic Kidney Diseases, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study the causes of Sickle Cell kidney disease, as well as to collect and store samples and information about people with Sickle Cell Disease.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2021-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04190888
The ClinicalTrials.gov registry entry for NCT04190888 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (73% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT04190888 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04190888 about?
NCT04190888 is a clinical study titled "Sickle Cell Uric Acid (SCUA) - Cohort Repository". The purpose of this research is to study the causes of Sickle Cell kidney disease, as well as to collect and store samples and information about people with Sickle Cell Disease.
What is the current status of trial NCT04190888?
This trial is currently completed. The enrollment target is 78 participants. The study started on 2019-07-01. Estimated completion is 2021-12-31.
What conditions does trial NCT04190888 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Chronic Kidney Diseases.
What interventions are being tested in trial NCT04190888?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT04190888?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04190888 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.